Vaccination against cervical cancer and other sequelae of human papillomaviruses

Česká verzia

Authors: T. Peterka
Authors place of work: Fakultní Thomayerova nemocnice, Praha ; Primář: MUDr. Tomáš Peterka ; Gynekologicko-porodnické oddělení
Published in the journal: Prakt. Lék. 2009; 89(1): 8-10
Category: Reviews

Summary

Vaccination against human papillomaviruses is a primary prevention against malignant lesions associated with HPV 16 and 18. The use of quadrivalent vaccines has the added value in also safeguarding against genital warts and other genital lesions induced by HPV 6 and 11. The best results are reached by vaccinating HPV-naive persons who have not come into contact with the most frequent sexually transmitted infections. Vaccination is also useful in older women.

Key words:
HPV, vaccination, cervical cancer, genital warts.

Zdroje

1. Bosh, F.X., Castellsague, X., Sanjosé, S. HPV and cervical cancer: screening or vaccination. Br. J. of Cancer 2008, 98, p. 15-21.

2. Crosbie, E.J., Kitchener, H.C. Cervarix – a bivalent L1 VLP vaccine for prevention of human papillomavirus type 16- and 18- associated cervical cancer. Expert Opin. Biol. Ther. 2007, 7, 3, p. 391-395.

3. Franco, E.L., Cucick, J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008, 265, A16-23.

4. Fraser, C., Tomassini, J.E., Xi, L. et al. Modeling the long-term antibody response of HPV VLP type 16 prophylactic vaccine. Vaccine 2007, 25, p. 4324-4333.

5. FUTURE II Study Group. Quadrivalent vaccine against HPV to prevent high-grade cervical lesions. N. Engl. J. Med. 2007, 356,19, p. 1915-1927.

6. Fait, T., Vrablík, M., Češka, R. a kol. Preventivní medicína. Praha: Maxdorf Jessenius, 2008, s. 554.

7. Garland, S.M., Hernandez-Avila, M., Wheeler, C.M. et al. Quadrivalent vaccine against HPV to prevent anogenital disease (FUTURE I). N. Engl. J. Med. 2007, 356, 19, p. 1928-1943.

8. Giannini, S.L., Hanon, E., Moris, P. et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 LV VLP vaccine formulated with the MLP/aluminium salt combination (AS04) comapred to aluminium salt only. Vaccine 2006, 24, p. 5937-5949.

9. Harper, M., Paavonen, J. Age for HPV vaccination. Vaccine 2008, 265, A7-11.

10. Joura, E.A., Leodolter, S., Hernandez-Avila, M. et al. Efficacy of quadrivalent prophylactic HPV (type 6, 11, 16, 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007, 369, p. 1693-1702.

11. Paavonen, J., Jenkins, D., Bosh, F.X. et al. Efficacy of a prophylactis adjuvanted bivalent L1 virus-like.particle vaccine against infection with human papillomavirus types 16 and 18 in young women. Lancet 2007, 369, p. 2161-2170.

12. Saslow, D., Castle, P.E., Cox, J.T. et al. American Cancer Society Guideline for HPV Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA Cancer J. Clin. 2007, 57, p. 7-28.

13. Villa. L,L., Ault. K,A., Giulian. A,R. Immunologic response following administration of a vaccine targeting HPV types 6, 11, 16 a 18. Vaccine 2006, 7, p. 557-583.

14. Villa, L.L., Costa, R.L.R., Petta, C.A. et al. High sustained efficacy of a prophylactic quadrivalent HPV type 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Brit. J. Cancer 2006, 95, p. 1459-1466.

15. Wright, T.C., Bosch, F.X. Is viral status needed before vaccination? Vaccine 2008, 265, A12-15.